My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Substances
Granisetron

Granisetron

A-Z
Search for:
Granisetron 1 AMPULES
Swiss Remedies
Substance Overview and History

Granisetron, a 5-HT3 receptor antagonist primarily used for chemotherapy-induced nausea, has shown potential in treating Alzheimer’s disease (AD). By blocking 5-HT3 receptors, granisetron reduces calcium influx and neuronal depolarization, mitigating calcium dyshomeostasis common in AD. Studies in TgSwDI mice demonstrated granisetron’s ability to enhance blood-brain barrier integrity, reduce amyloid-β accumulation, and alleviate neuroinflammation. These effects were linked to cognitive improvements and the normalization of calcium-related pathways like CamKII/CREB signaling, highlighting its disease-modifying potential.

References:

Al Rihani, S.B., Lan, R.S., & Kaddoumi, A. (2019) 'Granisetron alleviates Alzheimer’s disease pathology in TgSwDI mice through calmodulin-dependent protein kinase II/cAMP-response element binding protein pathway', Journal of Alzheimer’s Disease.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is Granisetron typically used for?
Granisetron is a 5-HT3 receptor antagonist commonly used to prevent chemotherapy-induced nausea and vomiting.
References:

Al Rihani, S.B., Lan, R.S., & Kaddoumi, A. (2019) 'Granisetron alleviates Alzheimer’s disease pathology in TgSwDI mice through calmodulin-dependent protein kinase II/cAMP-response element binding protein pathway', Journal of Alzheimer’s Disease.

How is Granisetron relevant to Alzheimer’s disease?
Research suggests it may protect against Alzheimer’s disease by enhancing blood-brain barrier (BBB) integrity, reducing amyloid-β (Aβ) accumulation, and mitigating calcium imbalance in neurons.
References:

Al Rihani, S.B., Lan, R.S., & Kaddoumi, A. (2019) 'Granisetron alleviates Alzheimer’s disease pathology in TgSwDI mice through calmodulin-dependent protein kinase II/cAMP-response element binding protein pathway', Journal of Alzheimer’s Disease.

What is the role of Granisetron in blood-brain barrier function?
Granisetron strengthens the BBB, preventing Aβ-induced damage and promoting Aβ clearance, which is crucial in reducing Alzheimer’s pathology.
References:

Al Rihani, S.B., Lan, R.S., & Kaddoumi, A. (2019) 'Granisetron alleviates Alzheimer’s disease pathology in TgSwDI mice through calmodulin-dependent protein kinase II/cAMP-response element binding protein pathway', Journal of Alzheimer’s Disease.